PerkinElmer unveils new offerings for detection and screening

PerkinElmer has expanded its portfolio with the purchase of assets from GE Healthcare.

Several Catalog Radiochemical, Scintillation Proximity Assay (SPA) reagent and Cytostar-T plate product lines will become part of PerkinElmer’s offering under the terms of the deal.

GE Healthcare’s Catalog Radiochemical products can be used to screen potential drug candidates through binding assays, while the SPA light-emitting assay and Cytostar-T plate technologies enable the automation of High Throughput Screening processes.

"PerkinElmer is delighted to announce this enhancement to our reagents assets," said Richard Elgen, president of bio-discovery at PerkinElmer.

"We expect that the incorporation of these technologies will strengthen our industry-leading GPCR and Kinase research product lines, and complement our HTS and research reagent solutions."

PerkinElmer posted revenues of approximately $2 billion (£1.2 billion) last year and recently confirmed details of a $15 million contract with the ITT Corporation Space Systems Division.